Close Menu

NEW YORK – Fluidigm said on Wednesday that it has completed the acquisition of InstruNor, a privately held, Oslo-based provider of integrated sample preparation systems for flow and mass cytometry.

Fluidigm purchased all outstanding shares of InstruNor for approximately $7.2 million, including $5.2 million in cash and approximately $2 million in stock.

InstruNor will become a part of Fluidigm's mass cytometry business, and Fluidigm said it expects the transaction to be accretive to earnings in 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.